Here's the naive question a smart friend would ask: how does one injection make you eat less? The short version is that it impersonates hormones your gut already makes. After a meal, your intestine releases signaling molecules — GLP-1 and GIP among them — that tell the pancreas to release insulin, slow how fast the stomach empties, and signal the brain that you're full. Tirzepatide is a lab-made peptide that mimics two of those signals at once.
Think of it like a key cut to fit two locks. Most earlier drugs in this class (semaglutide, for instance) fit the GLP-1 lock alone. Tirzepatide is engineered to turn both the GLP-1 and the GIP receptor — which is why it's called a dual agonist, or co-agonist. In plain terms, it pushes on two of the body's satiety-and-glucose levers simultaneously, and in trials that combination produced larger effects on blood sugar and weight than single-target drugs.
The intellectual property behind this isn't abstract. Eli Lilly's granted patent US12616740B2, "Methods of using a GIP/GLP1 co-agonist for therapy" (issued May 5, 2026), claims methods of using a molecule that hits both receptors. A patent like this matters because the molecule is only half the franchise — how and for what you are allowed to use it is the other half, and method-of-use claims are a standard way drugmakers extend and defend a product.
Lilly is not alone in chasing the dual- and triple-receptor idea, and the patent record shows it. Sun Pharmaceutical holds its own granted US12622948B2 on "GLP-1/GIP dual agonists," and a published application, US20260151493A1, describes going a step further — tri-agonists that hit GLP-1, GIP, and the amylin receptor. The field is racing from one lock to two to three.
Why should a non-specialist care about the receptor count? Because each added target is a bet that more levers means more effect — and a fresh opportunity to file patents. The metabolic-drug war is being fought partly in the clinic and partly in the patent office, and the grants tell you where the science is heading even before the next product launches.
So when you read that a new obesity drug is "more powerful," translate it: it usually means the molecule activates more of these gut-hormone receptors, or activates them more durably. The mechanism is not magic. It's a peptide standing in for the signals your body sends after dinner — and a stack of patents making sure a competitor can't copy the trick.